Celcuity reports positive Phase 1 data for prostate cancer therapy
PositiveFinancial Markets

Celcuity has announced promising Phase 1 data for its new therapy targeting prostate cancer, marking a significant step forward in treatment options for patients. This development is crucial as it highlights the potential for innovative therapies to improve outcomes in a disease that affects many men worldwide.
— Curated by the World Pulse Now AI Editorial System